<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993625</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2021-02-102</org_study_id>
    <nct_id>NCT04993625</nct_id>
  </id_info>
  <brief_title>Selective Omission of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm studyTrial</brief_title>
  <official_title>Selective Omission of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeong Eon Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel&#xD;
      lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast&#xD;
      cancer patients when physical examination expected complete remission. And radiological&#xD;
      expected Tumor size ≤ 2cm or non-mass enhancement ≤ 4cm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year recurrence free survival</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when expected complete remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LRFS</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year local recurrence-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSS</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year cancer-specific survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBTR</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year ipsilateral breast tumor recurrence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IARI</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year ipsilateral axillary recurrence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity rate</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year cumulative toxicity rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>5-year after last patient enrollment</time_frame>
    <description>5-year quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy</intervention_name>
    <description>Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla</description>
    <arm_group_label>Avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. undergone neoadjuvant chemotherapy&#xD;
&#xD;
          2. HER-2 or triple negative breast cancer&#xD;
&#xD;
          3. clinical stage T1-3, N0-1, M0 (AJCC 8th)&#xD;
&#xD;
          4. not Inflammatory breast cancer&#xD;
&#xD;
          5. neoadjuvant chemotherapy should be done before surgery(sandwich method is not allowed)&#xD;
&#xD;
               -  least four times anthacycline or taxane-based regimens&#xD;
&#xD;
               -  no axilla lesion progression during chemotherapy&#xD;
&#xD;
               -  no period of adverse response during chemotherapy&#xD;
&#xD;
          6. undergone anti HER-2 therapy in HER-2 positive patient&#xD;
&#xD;
          7. no preoperative anti hormonal therapy&#xD;
&#xD;
          8. no preoperative radiation therapy&#xD;
&#xD;
          9. did not axillary lymph node biopsy before neoadjuvant chemotherapy&#xD;
&#xD;
         10. physical examination expected complete remission. And radiological expected Tumor size&#xD;
             ≤ 2cm or non-mass enhancement ≤ 4cm&#xD;
&#xD;
         11. no previous axilla surgery&#xD;
&#xD;
         12. no previous ipsilateral breast surgery for invasive cancer&#xD;
&#xD;
         13. no Pregnancy-associated breast cancer&#xD;
&#xD;
         14. ECOG performance status 0-1&#xD;
&#xD;
         15. Serum or urine b-HCG negative&#xD;
&#xD;
         16. agree to the consent form&#xD;
&#xD;
         17. 20≤Age&lt;70&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. During pregnancy&#xD;
&#xD;
          2. major depression or taking psychiatric medication&#xD;
&#xD;
          3. significant psychiatric disorder or history of taking antipsychotic drugs&#xD;
&#xD;
          4. any other lymph node metastasis than axillary lesion&#xD;
&#xD;
          5. undergoing total mastectomy&#xD;
&#xD;
          6. do not agree to the consent form&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Eon Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong Eon Lee, MD, PhD</last_name>
    <phone>+82-10-9933-0260</phone>
    <email>paojlus@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raejin Lee</last_name>
    <phone>+82-70-7014-4154</phone>
    <email>raejin.lee@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Eon Lee, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeong Eon Lee</investigator_full_name>
    <investigator_title>Samsung Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

